Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. Moberg Pharma’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).

Moberg Pharma’s main asset, MOB-015 (Terclara®), is a groundbreaking, patented 10% topical terbinafine treatment for onychomycosis (nail-fungus). The drug is currently registered in 13 European countries, whereof 7 as OTC, 6 as Rx. 

We have introduced MOB-015 under the brand Terclara in our home market Sweden and Norway and immediately achieved market leadership. Terclara now holds >40 percent value share in both markets and has grown the total market for nail fungus treatments significantly.

What makes MOB-015 unique:

• Delivers terbinafine to the nail bed at concentrations ~40x higher than oral treatment
• Fungicidal effect with the highest reported mycological cure rate (76%) among available treatments
• Visible clinical improvement within weeks